Skip to main content
ImmuneCited

Pelargonium sidoides für Acute Bronchitis

A

Meta-analyses demonstrate Pelargonium sidoides (EPs 7630) may significantly reduce bronchitis symptom severity and working inability. Approved as a medicine for respiratory infections in multiple countries. RCT showed working inability decreased to 16% vs 43% in placebo group after 7 days.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'immunecited.com'; const params = 'ingredient\u003Dpelargonium\u002Dsidoides\u0026condition\u003Dacute\u002Dbronchitis'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

Fazit

Meta-analyses demonstrate Pelargonium sidoides (EPs 7630) may significantly reduce bronchitis symptom severity and working inability. Approved as a medicine for respiratory infections in multiple countries. RCT showed working inability decreased to 16% vs 43% in placebo group after 7 days.

Key Study Findings

Other
Research Landscape and Emerging Trends in Herbal Medicine for Pediatric Respiratory Tract Infections: A CiteSpace-Based …
Dose: None vs.: None Outcome: research landscape of herbal medicine for pediatric RTIs Wirkung: None None

Population: pediatric patients with respiratory tract infections

Systematic Review
Pelargonium sidoides - from ethnopharmacology to evidence-based medicine: a systematic review.
Dose: None vs.: None Outcome: clinical efficacy of Pelargonium sidoides for respiratory tract … Wirkung: None None

Population: patients with acute bronchitis, rhinosinusitis, and tonsillopharyngitis

Randomized Controlled Trial n=240 1 weeks Double-blind
Efficacy and Safety of YJP-40 in Patients with Acute Bronchitis: A Randomized, Double-Blind, Parallel Group …
Dose: None vs.: Umckamin syrup (P. sidoides extract alone) Outcome: Change in bronchitis severity score (BSS) at day … Wirkung: BSS change: -4.31 vs -4.36 non-inferiority demonstrated

Population: Patients with acute bronchitis from 7 hospitals

Randomized Controlled Trial 1 weeks Double-blind
Efficacy and safety of mixture of ivy leaf extract and coptidis rhizome in the treatment …
Dose: Ivy leaf extract + Coptidis rhizome vs.: Pelargonium sidoides extract Outcome: Bronchitis severity score (BSS) Wirkung: None None

Population: Adults with acute bronchitis

Review
Chronobiological Efficacy of Combined Therapy of Pelargonium Sidoides and Melatonin in Acute and Persistent Cases …
Dose: None vs.: None Outcome: inflammation markers Wirkung: None None

Population: Covid-19

Randomized Controlled Trial n=591 1.0 weeks Open-label
Safety of Pelargonium extract EPs 7630 in young children with acute bronchitis.
Dose: 7.2% vs.: None Outcome: None Wirkung: None None

Population: Ab received eps 7630 syrup or solution for 7 days

Key Statistics

8

Studien

2000

Teilnehmer

Positive

A

Bewertung

Referenced Papers

The Cochrane database … 2013 125 Zitierungen
Phytomedicine : international … 2008 100 Zitierungen
The Cochrane database … 2008 71 Zitierungen
Phytomedicine : international … 2007 39 Zitierungen
Wiener medizinische Wochenschrift … 2007 23 Zitierungen

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Übliche Dosierungen

general:
30 drops (1.5 mL) liquid extract 3x/day or 20 mg EPs 7630 tablets 3x/day
duration:
7-14 days

Obergrenze: No established UL

In der Forschung untersuchte Dosierungen

Dosierung Dauer Wirkung N
None -- Positive --
None -- Positive --
None 1 weeks Neutral 240
Ivy leaf extract + Coptidis rhizome 1 weeks Positive --
None -- Mixed --
7.2% 1.0 weeks Positive 591
83.6% 10.4 weeks Mixed 505
None -- Positive 2195

Beste Einnahmezeit: At onset of respiratory symptoms; 3x daily for up to 14 days

Safety & Side Effects

Gemeldete Nebenwirkungen

  • Gastrointestinal discomfort (rare)
  • Allergic skin reactions (rare)
  • Nosebleeds (rare)
  • Hepatotoxicity (very rare, case reports)

Bekannte Wechselwirkungen

  • Anticoagulants (theoretical increased bleeding risk due to coumarin content)
  • Immunosuppressant medications (may modulate immune function)

Tolerierbare Höchstaufnahmemenge: No established UL

Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.

Frequently Asked Questions

Does Pelargonium sidoides help with Acute Bronchitis?
Based on 8 studies with 2,000 participants, there is strong evidence from multiple clinical trials that Pelargonium sidoides may support Acute Bronchitis management. Our evidence grade is A (Strong Evidence).
How much Pelargonium sidoides should I take for Acute Bronchitis?
Studies have used various dosages. A commonly studied range is 30 drops (1.5 mL) liquid extract 3x/day or 20 mg EPs 7630 tablets 3x/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Pelargonium sidoides?
Reported side effects may include Gastrointestinal discomfort (rare), Allergic skin reactions (rare), Nosebleeds (rare), Hepatotoxicity (very rare, case reports). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Pelargonium sidoides and Acute Bronchitis?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 8 peer-reviewed studies with 2,000 total participants. The overall direction of effect is positive.

Related Evidence

Andere Inhaltsstoffe für Acute Bronchitis

FDA-Haftungsausschluss: Diese Aussagen wurden nicht von der Food and Drug Administration bewertet. Die Produkte und Informationen auf dieser Website sind nicht dazu bestimmt, Krankheiten zu diagnostizieren, zu behandeln, zu heilen oder zu verhindern. Die dargestellten Evidenzbewertungen basieren auf unserer Analyse veröffentlichter begutachteter Forschung und stellen keine medizinische Beratung dar. Konsultieren Sie immer Ihren Arzt, bevor Sie mit der Einnahme von Nahrungsergänzungsmitteln beginnen.